ICHR vs UCTT: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
UCTT is the larger of the two ($1.79B market cap): the incumbent the market prices for continued execution (5.70x forward earnings, beta 1.92). ICHR is the smaller challenger ($1.05B), actually pricier on forward earnings (8.06x): more room to run, but more to prove. On the numbers, UCTT leads on both counts: faster expected revenue growth (40% vs 32%) and a lower forward P/E (5.7x vs 8.06x). The case for ICHR rests on its own driver (Semiconductor capital equipment recovery): if you believe in that, ICHR fits; if you believe in what the numbers show today, UCTT does.
ICHR vs UCTT: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ICHR | UCTT | What it tells you |
|---|---|---|---|
| Market cap | $1.05B | $1.79B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 8.06 | 5.70 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 399.36 | 64.47 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.90 | 1.92 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 14% of range | 13% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.18 | 2.35 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: UCTT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how ICHR and UCTT affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ICHR and UCTT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ICHR and UCTT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Ichor Holdings (ICHR) do?
Ichor Holdings designs, engineers, and manufactures critical fluid delivery subsystems and components used in the tools that make semiconductors. Its core products are gas delivery subsystems (which deliver, monitor, and control the specialty gases used in etch and deposition) and chemical delivery subsystems (which blend and dispense the reactive liquids used in electroplating and cleaning). Ichor is a turnkey outsourcing partner to major original equipment manufacturers, letting them hand off non-critical elements of tool design, production, and support. The company is headquartered in Fremont, California, and was incorporated in 1999.
What does Ultra Clean Holdings (UCTT) do?
Ultra Clean Holdings (Nasdaq: UCTT) builds production tools, gas and chemical delivery systems, process modules, and other subsystems that go inside the machines its customers use to manufacture semiconductors. The business splits into a Products division (integrated outsourced subassemblies and high-precision manufacturing, the large majority of revenue) and a smaller Services division (tool chamber parts cleaning, coating, and micro-contamination analysis). Its customers are the big wafer fab equipment makers, and the company is a classic outsourced supplier, meaning its results rise and fall with how much its handful of large customers are spending.
ICHR vs UCTT: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- ICHR drivers: Semiconductor capital equipment recovery; Margin expansion through proprietary content.
- UCTT drivers: AI-driven WFE upcycle; Leading-edge and advanced packaging demand.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Customer concentration is severe: Lam Research and Applied Materials together account for the large majority of revenue (roughly 87 percent by one industry estimate), so a pullback in orders from either would hit results hard. For UCTT, customer concentration is the defining risk: the top few clients regularly account for over 70 percent of revenue, so losing share at, or a spending pullback from, a single large customer can swing results dramatically.
ICHR or UCTT: which should you pick?
If the story you believe is ICHR's (Semiconductor capital equipment recovery), ICHR is the more direct way to own it; if it is UCTT's (AI-driven WFE upcycle), UCTT is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ICHR and UCTT guides.
ICHR vs UCTT: the full fundamentals
ICHR. As of November 20, 2026 Ichor carries a market cap near $1.05 billion on about $1.1 billion of trailing revenue, roughly 0.95 times sales, down from about 1.65 times in mid-October and about 3.5 times in May. Trailing GAAP profit is barely positive, so the valuation leans on analysts' forecasts of about $1.84 of EPS in 2026 and $3.47 in 2027, which put the forward multiple near 8x. Cash of about $213.5 million still exceeds debt of roughly $119-152 million, and the eight analysts Yahoo Finance tracks have a mean target near $68.
UCTT. The valuation has swung from rich to cheap in a few months: at about $5.4 billion in mid-2026 the market cap was over 2.5 times trailing revenue, and at about $1.8 billion in November it is near 0.74 times. Trailing GAAP earnings have only just turned positive, so the trailing P/E near 65 says little, while the stock trades at about 5.7 times consensus 2027 EPS of $6.56. That low forward multiple prices in real doubt about how long the WFE upcycle lasts and about cash burn, and the average analyst target of about $106 from seven analysts sits far above both the price and Barclays' $65.
Headline figures (approximate, November 2026): ICHR shows revenue (ttm) ~$1.1B, q3 2026 revenue ~$329M (+~37% y/y), q3 2026 non-gaap gross margin ~16%, q3 2026 non-gaap eps ~$0.63 vs ~$0.45 expected; UCTT shows revenue (ttm) ~$2.44B; Q3 2026 up ~49% YoY, q3 2026 revenue ~$759M (Q2 2026 ~$645M), q3 2026 non-gaap eps $1.15 vs $0.94 expected, net income (ttm) ~$27M GAAP (trailing EPS ~$0.58).
The bottom line: ICHR vs UCTT
ICHR and UCTT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ICHR and UCTT exposure against your real portfolio. It is not an investment adviser.
Wondering how ICHR or UCTT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Ichor Holdings
Ask Walnut's AI anything about ICHR and see how it fits what you own.
FAQ
What is the difference between ICHR and UCTT?
+
Ichor Holdings designs, engineers, and manufactures critical fluid delivery subsystems and components used in the tools that make semiconductors. Ultra Clean Holdings (Nasdaq: UCTT) builds production tools, gas and chemical delivery systems, process modules, and other subsystems that go inside the machines its customers use to manufacture semiconductors. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ICHR or UCTT the better stock?
+
Neither is universally better. UCTT is the larger incumbent; ICHR is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ICHR or UCTT?
+
On forward P/E (as of November 2026), ICHR trades at 8.06x and UCTT at 5.70x, so UCTT is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ICHR and UCTT?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ICHR vs UCTT?
+
ICHR: Customer concentration is severe: Lam Research and Applied Materials together account for the large majority of revenue (roughly 87 percent by one industry estimate), so a pullback in orders from either would hit results hard. The business is deeply cyclical and tied to volatile fab equipment spending, and gross margins in the low-to-mid teens leave little cushion when volumes fall. Ichor posted a GAAP net loss in 2025 and is only barely profitable on a trailing twelve-month basis (about $3.5 million), and trailing operating cash flow is negative (about -$38 million) as inventory builds for the ramp. Supplier bottlenecks are a fresh risk: delayed shipments cost Ichor its revenue estimate in Q2 and it fell just short of consensus revenue again in Q3, and the stock has fallen about 76% from its 52-week high, which shows how heavily the market is weighing revenue execution. The roughly $195 million at-the-market offering diluted holders, and insiders including the COO sold shares in August and September. Additional risks include input cost pressure, geographic exposure to Asian semiconductor supply chains, potential export controls or trade restrictions, and competition from larger, better-capitalized subsystem suppliers. UCTT: Customer concentration is the defining risk: the top few clients regularly account for over 70 percent of revenue, so losing share at, or a spending pullback from, a single large customer can swing results dramatically. Margins are structurally thin (gross margin around 16% and profit margin near 1% on a trailing basis), leaving little cushion in a downturn, and full-year 2025 GAAP results included a large non-cash goodwill impairment that produced a net loss. The semiconductor equipment cycle is highly volatile, so a slowdown in WFE spending would hit revenue and earnings hard. The stock rose very sharply in 2026 and then fell about 74% from its 52-week high of roughly $144 to about $38 by November 20, even as the September quarter beat estimates, which shows how quickly sentiment can reverse while estimates rise. Cash flow is the other pressure point: trailing operating cash flow was about -$109 million and free cash flow about -$143 million, and the balance sheet carries about $810 million of debt against roughly $271 million of cash. Not every analyst is constructive; Barclays initiated coverage on November 13, 2026 at Equalweight with a $65 target. The company also carries the usual supply-chain, pricing-power, and geographic-exposure risks of an outsourced hardware supplier.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ICHR or UCTT; figures are approximate and dated (as of November 2026). Verify current data before investing.